• 1
    AstraZeneca. Annual Report and Form 20-F, 2000. London: AstraZeneca, 2001.
  • 2
    Blankenhorn K, Lipson D. Business watch: 2001 in review: despite economic challenges, pharmaceutical industry still maintains steady growth. Med Mark Med 2002; 37: 4762.
  • 3
    Agreus L, Borgquist L. The cost of gastro-oesophageal reflux disease, dyspepsia and peptic ulcer disease in Sweden. Pharmacoeconomics 2002; 20: 34755.
  • 4
    Department of Health. Prescription Cost Analysis: England 2002. London: Department of Health, 2003.
  • 5
    Boath EH, Blenkinsopp A. The rise and rise of proton pump inhibitor drugs: patients’ perspectives. Soc Sci Med 1997; 45: 15719.
  • 6
    Westbrook JI, Duggan AE, McIntosh JH. Prescriptions for antiulcer drugs in Australia: volume, trends, and costs. BMJ 2001; 323: 13389.
  • 7
    McManus P, Marley J, Birkett DJ, Lindner J. Compliance with restrictions on the subsidized use of proton pump inhibitors in Australia. Br J Clin Pharmacol 1998; 46: 40911.
  • 8
    Lassen A, Hallas J, Schaffalitzky De Muckadell OB. Use of anti-secretory medication: a population-based cohort study. Aliment Pharmacol Ther 2004; 20: 57783.
  • 9
    Zermansky AG. Who controls repeats? Br J Gen Pract 1996; 46: 6437.
  • 10
    Harris CM, Dajda R. The scale of repeat prescribing. Br J Gen Pract 1996; 46: 64953.
  • 11
    Bashford JN, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ 1998; 317: 4526.
  • 12
    Pollock K, Grime J. The cost and cost-effectiveness of PPIs – GP perspectives and responses to a prescribing dilemma and their implications for the development of patient-centred healthcare. Eur J Gen Pract 2003; 9: 140.
  • 13
    Martin RM, Lim AG, Kerry SM, Hilton SR. Trends in prescribing H2-receptor antagonists and proton pump inhibitors in primary care. Aliment Pharmacol Ther 1998; 12: 797805.
  • 14
    Raghunath AS and Hungin APS. Proton Pump inhibitors Understanding the prescribing behaviour of general practitioners. Gut 2001; 49 (Suppl. 3): A1461.
  • 15
    Grime J, Pollock K, Blenkinsopp A. Proton pump inhibitors: perspectives of patients and their GPs. Br J Gen Pract 2001; 51: 70311.
  • 16
    Goudie BM, McKenzie PE, Cipriano J, Griffin EM, Murray FE. Repeat prescribing of ulcer healing drugs in general practice – prevalence and underlying diagnosis. Aliment Pharmacol Ther 1996; 10: 14750.
  • 17
    Boutet R, Wilcock M, MacKenzie I. Survey on repeat prescribing for acid suppression drugs in primary care in Cornwall and the Isles of Scilly. Aliment Pharmacol Ther 1999; 13: 8137.
  • 18
    Ryder SD, O'Reilly S, Miller RJ, Ross J, Jacyna MR, Levi AJ. Long term acid suppressing treatment in general practice. BMJ 1994; 308: 82730.
  • 19
    Hurenkamp GJ, Grundmeyer HG, Bindels PJ, Tytgat GN, Van Der Hulst RW. How do primary care physicians use long-term acid suppressant drugs? A population-based analysis of Dutch general practices. J Fam Pract 2002; 51: 2415.
  • 20
    Rubin GP, Contractor B, Bramble MG. The use of long-term acid-suppression therapy. Br J Clin Pract 1995; 49: 11920.
  • 21
    Hungin AP, Rubin GP, O'Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 1999; 49: 4513.
  • 22
    Raghunath AS and Hungin APS. Long-term prescribing of proton pump inhibitors in primary care: a cross-sectional survey. Gut 2004; 53 (Suppl. 111): A24.
  • 23
    Prach AT, McGilchrist MM, Murray FE, Johnston DA, MacDonald TM. Prescription of acid-suppressing drugs in relation to endoscopic diagnosis: a record-linkage study. Aliment Pharmacol Ther 1999; 13: 397405.
  • 24
    Majumdar SR, Soumerai SB, Farraye FA, et al. Chronic acid-related disorders are common and underinvestigated. Am J Gastroenterol 2003; 98: 240914.
    Direct Link:
  • 25
    Bardhan KD. Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98: S40S48.
  • 26
    Wilhelmsen I, Hatlebakk JG, Olafsson S, Berstad A. On demand therapy of reflux oesophagitis – a prospective study of symptoms, patient satisfaction and quality of life. Aliment Pharmacol Ther 1999; 13: 103540.
  • 27
    Tsai HH, Chapman R, Shepherd A, et al. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study. Aliment Pharmacol Ther 2004; 20: 65765.
  • 28
    Chen TJ, Chou LF, Hwang SJ. Trends in prescribing proton pump inhibitors in Taiwan: 1. Int J Clin Pharmacol Ther 2003; 41: 20712.
  • 29
    Roberts SJ, Bateman DN. Prescribing of antacids and ulcer-healing drugs in primary care in the north of England. Aliment Pharmacol Ther 1995; 9: 13743.
  • 30
    Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC. Who is using chronic acid suppression therapy and why? Am J Gastroenterol 2003; 98: 518.
    Direct Link:
  • 31
    Lassen A, Hallas J, de Muckadell OB. Eradication of Helicobacter pylori and use of antisecretory drugs: population based cohort study. BMJ 2003; 327: 603.
  • 32
    Moayyedi P, Soo S, Deeks J, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ 2000; 321: 65964.
  • 33
    NICE guideline. Dyspepsia: Managing Dyspepsia in Adults in Primary Care. Newcastle-upon-Tyne: National Guideline Research and Development Unit, University of Newcastle-upon-Tyne, 2004.
  • 34
    Hungin AP, Rubin G, O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999; 49: 4634.
  • 35
    Lee TJ, Fennerty MB, Howden CW. Systematic review: is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease? Aliment Pharmacol Ther 2004; 20: 124151.
  • 36
    Cooper AL, Langworthy H, Porter S. Cost-effective prescribing of proton pump inhibitor therapy: an audit in general practice. Int J Clin Pract 2000; 54: 28792.
  • 37
    Chan J, Hui RL, Szpakowski JL. Prescribing proton pump inhibitors for initial treatment of acid-related gastrointestinal diseases in a managed care population. Am J Manag Care 2004; 10: 43341.
  • 38
    Krol N, Wensing M, Haaijer-Ruskamp F, et al. Patient-directed strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial. Aliment Pharmacol Ther 2004; 19: 91722.
  • 39
    Raghunath AS, Hungin AP, Jackson W. Dyspepsia symptoms and quality of life in patients on long-term proton pump inhibitors – influence of H. pylori status. Gut 2004; 53 (Suppl. V1): 286.
  • 40
    Peters FT, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut 1999; 45: 48994.
  • 41
    Malesci A, Savarino V, Zentilin P, et al. Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 1996; 44: 7005.
  • 42
    Gore S, Healey CJ, Sutton R, et al. Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 1993; 7: 6238.
  • 43
    Wilkinson SP, Biddlestone L, Gore S, Shepherd NA. Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy. Aliment Pharmacol Ther 1999; 13: 12059.
  • 44
    Fitzgerald RC, Lascar R, Triadafilopoulos G. Review article: Barrett's oesophagus, dysplasia and pharmacologic acid suppression. Aliment Pharmacol Ther 2001; 15: 26976.
  • 45
    Bateman DN, Colin-Jones D, Hartz S, et al. Mortality study of 18 000 patients treated with omeprazole. Gut 2003; 52: 9426.
  • 46
    Spiller R. Digest. Gut 2003; 52: 917a.
  • 47
    AstraZeneca. Annual Report and Form 20-F Information 2003. London: AstraZeneca, 2004.
  • 48
    Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 1986; 35 (Suppl. 1): 4255.
  • 49
    Carlsson E, Havu N, Mattsson H, Ekman L. Gastrin and gastric enterochromaffin-like cell carcinoids in the rat. Digestion 1990; 47 (Suppl. 1): 1723.
  • 50
    Metz DC. Managing gastroesophageal reflux disease for the lifetime of the patient: evaluating the long-term options. Am J Med 2004; 117 (Suppl. 5A): 49S55S.
  • 51
    Maton PN. Omeprazole. N Engl J Med 1991; 324: 96575.
  • 52
    Ligumsky M, Lysy J, Siguencia G, Friedlander Y. Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis. J Clin Gastroenterol 2001; 33: 325.
  • 53
    Robinson M. Review article: current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia. Aliment Pharmacol Ther 1999; 13 (Suppl. 5): 510.
  • 54
    Bateson MC. Hypergastrinaemia with long-term omeprazole treatment. Aliment Pharmacol Ther 1999; 13: 4401.
  • 55
    Reilly JP. Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm 1999; 56: S11S17.
  • 56
    Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994; 35: 5908.
  • 57
    Freston JW, Rose PA, Heller CA, Haber M, Jennings D. Safety profile of Lansoprazole: the US clinical trial experience. Drug Saf 1999; 20: 195205.
  • 58
    Havu N. Gastric morphology during long-term omeprazole therapy. Gastroenterology 1998; 114: A145 (Abstract).
  • 59
    Sanduleanu S, Stridsberg M, Jonkers D, et al. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther 1999; 13: 14553.
  • 60
    Waldum HL, Brenna E. Personal review: is profound acid inhibition safe? Aliment Pharmacol Ther 2000; 14: 1522.
  • 61
    Graham JR. Gastric polyposis: onset during long-term therapy with omeprazole. Med J Aust 1992; 157: 2878.
  • 62
    Choudhry U, Boyce HW Jr, Coppola D. Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. Am J Clin Pathol 1998; 110: 61521.
  • 63
    el Zimaity HM, Jackson FW, Graham DY. Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol 1997; 92: 185860.
  • 64
    Stolte M. Fundic gland polyps: a rare, innocuous, and reversible disturbance. Gastroenterology 1993; 105: 15901.
  • 65
    Vieth M, Stolte M. Fundic gland polyps are not induced by proton pump inhibitor therapy. Am J Clin Pathol 2001; 116: 71620.
  • 66
    Pashankar DS, Israel DM. Gastric polyps and nodules in children receiving long-term omeprazole therapy. J Pediatr Gastroenterol Nutr 2002; 35: 65862.
  • 67
    Kazantsev GB, Schwesinger WH, Heim-Hall J. Spontaneous resolution of multiple fundic gland polyps after cessation of treatment with lansoprazole and Nissen fundoplication: a case report. Gastrointest Endosc 2002; 55: 6002.
  • 68
    Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Bea L. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 101822.
  • 69
    Berstad AE, Hatlebakk JG, Maartmann-Moe H, Berstad A, Brandtzag P. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Gut 1997; 41: 7407.
  • 70
    Eissele R, Brunner G, Simon B, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997; 112: 70717.
  • 71
    Lundell L. Lack of effect of acid suppression therapy on gastric atrophy. Gastroenterology 2000; 118: 453.
  • 72
    Pounder RE, Williams MP. Omeprazole and accelerated onset of atrophic gastritis. Gastroenterology 2000; 118: 2389.
  • 73
    McColl KE, Murray LS, Gillen D. Omeprazole and accelerated onset of atrophic gastritis. Gastroenterology 2000; 118: 239.
  • 74
    Singh P, Indaram A, Greenberg R, Visvalingam V, Bank S. Long term omeprazole therapy for reflux esophagitis:follow-up in serum gastrin levels, EC cell hyperplasia and neoplasia. World J Gastroenterol 2000; 6: 78992.
  • 75
    Geboes K, Dekker W, Mulder CJ, Nusteling K. Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa. Aliment Pharmacol Ther 2001; 15: 181926.
  • 76
    Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Mashiba H, et al. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan. Aliment Pharmacol Ther 2000; 14: 134552.
  • 77
    Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, Snel P, Goldfain D, Kolkman JJ, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004; 53: 1220.
  • 78
    FDC. Proton pump inhibitor relabelling for cancer risk not warranted. FDC Report, 11 November, 1996.
  • 79
    Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of H. pylori infection – the Maastricht 2–2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 16780.
  • 80
    McColl KE. Helicobacter pylori infection and long term proton pump inhibitor therapy. Gut 2004; 53: 57.
  • 81
    Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 7849.
  • 82
    Hojo M, Miwa H, Ohkusa T, Ohkura R, Kurosawa A, Sato N. Alteration of histological gastritis after cure of Helicobacter pylori infection. Aliment Pharmacol Ther 2002; 16: 192332.
  • 83
    Moayyedi P, Wason C, Peacock R, et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 2000; 5: 20614.
  • 84
    Gillen D, Wirz AA, Ardill JE, McColl KE. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999; 116: 23947.
  • 85
    Gillen D, Wirz AA, McColl KE. Helicobacter pylori eradication releases prolonged increased acid secretion following omeprazole treatment. Gastroenterology 2004; 126: 9808.
  • 86
    Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996; 39: 549.
  • 87
    Sanduleanu S, Jonkers D, De Bruine A, Hameeteman W, Stockbrugger RW. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther 2001; 15: 37988.
  • 88
    Patel TA, Abraham P, Ashar VJ, Bhatia SJ, Anklesaria PS. Gastric bacterial overgrowth accompanies profound acid suppression. Indian J Gastroenterol 1995; 14: 1346.
  • 89
    Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. LAHEIJ2004. JAMA 2004; 292: 195560.
  • 90
    Laheij RJ, Van Ijzendoorn MC, Janssen MJ, Jansen JB. Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther 2003; 18: 84751.
  • 91
    Sanduleanu S, Jonkers D, De Bruine A, Hameeteman W, Stockbrugger RW. Double gastric infection with Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and dvelopment of atrophic gastritis. Aliment Pharmacol Ther 2001; 15: 116375.
  • 92
    Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004; 57: 4228.
  • 93
    Sipponen P, Laxen F, Huotari K, Harkonen M. Prevalence of low vitamin B12 and high homocysteine in serum in an elderly male population: association with atrophic gastritis and Helicobacter pylori infection. Scand J Gastroenterol 2003; 38: 120916.
  • 94
    Cui GL, Syversen U, Zhao CM, Chen D, Waldum HL. Long-term omeprazole treatment supresses body weight gain and bone mineralisation in young male rats. Scand J Gastroenterol 2001; 36: 101115.
  • 95
    Vetvik K, Straand J. Acid-related disease in the population of two Norwegian municipalities – diagnosis and drug therapy. Tidsskr Nor Laegeforen 2001; 121: 55762.
  • 96
    Ahnfeldt-Mollerup I, Fly GF, Knudsen MH. Dyspepsia in general practice. A study among users of anti-ulcer agents. Ugeskr Laeger 1997; 159: 37726.